Oncology News | pharmaphorum

News

Daiichi Sankyo and AstraZeneca's Enhertu has become the first new first-line option in the US for HER2-positive breast cancer in more than a decade.

News

The FDA has awarded its latest national priority voucher to Johnson & Johnson for a combination regimen based on Tecvayli for multiple myeloma.

News

Biotech financings this week include SanegeneBio's Lilly-backed $110m Series B, with Sidera, D3 Bio, BlossomHill, and Prolynx also raising new funds.

News

Pfizer's Tukysa looks poised to find a new role as first-line maintenance therapy for HER2-positive metastatic breast cancer.

News

Roche reveals the data that has it excited about giredestrant in early-stage breast cancer, but how might it be positioned versus CDK4/6 inhibitors?

News

The FDA could make it harder for developers of CAR-T therapies to bring them to market by requiring full randomised controlled trials.